Mateos, M., Robak, P., Hus, M., Fu, C., Zherebtsova, V., Ward, C., Ho, P. J., Hajek, R., Kim, K., Dimopoulos, M. A., Cerchione, C., Pirooz, N., McKeown, A., Lin, C. P., Baig, H., Eccersley, L., Roy-Ghanta, S., Opalinska, J., Hungria, V. (2025). DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7546